Results 21 to 30 of about 3,081 (193)

Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China

Frontiers in Immunology, 2023
IntroductionBruton tyrosine kinase inhibitor (BTKi) has demonstrated substantial efficacy in treating B-cell lymphoproliferative diseases (BLPD). Nonetheless, the significant discontinuation rates due to toxicity or financial reasons cannot be overlooked.
Yuting Yan, Yuting Yan, Rui Lv, Rui Lv, Tingyu Wang, Tingyu Wang, Ying Yu, Ying Yu, Yanshan Huang, Yanshan Huang, Wenjie Xiong, Wenjie Xiong, Yuxi Li, Yuxi Li, Weiwei Sui, Weiwei Sui, Qi Wang, Qi Wang, Wenyang Huang, Wenyang Huang, Gang An, Gang An, Dehui Zou, Dehui Zou, Jianxiang Wang, Jianxiang Wang, Lugui Qiu, Lugui Qiu, Shuhua Yi, Shuhua Yi   +29 more
doaj   +1 more source

Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies. [PDF]

Rev Cardiovasc Med
Bruton's tyrosine kinase (BTK) inhibitors are important targeted drugs for treating chronic B-cell malignancies, and have played a key role in improving patient prognosis and treatment efficacy. However, despite the significant advantages of BTK inhibitors in anti-tumor therapy, the use of these drugs also promotes certain cardiovascular risks ...
Gan H, Lin J, Sun Q, Xu J, He Q, Chen S, Feng Y, Hu B, Wang W.   +8 more
europepmc   +2 more sources

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases. [PDF]

MedComm (2020)
BTK inhibitors suppress malignant B‐cell signaling while simultaneously reshaping immune regulation through effects on T cells and the tumor microenvironment. These mechanisms support combination immunotherapy strategies and also underlie the expanding application of BTK inhibitors in solid tumors, autoimmune and inflammatory diseases.
Sun M, Li D, Wei J.
europepmc   +2 more sources

Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis

Scientific Reports, 2023
The efficacy of Bruton tyrosine kinase inhibitors (BTKi) remains suboptimal in chronic lymphocytic leukemia (CLL) treatment. A systematic review and meta-analysis were conducted to compare the outcomes of combining anti-CD20 monoclonal antibodies (mAb ...
Thi Thuy Nguyen, Nguyen Thanh Nhu, Van Khoi Tran, Nguyen-Kieu Viet-Nhi, Xuan Dung Ho, Ming-Kai Jhan, Ya-Ping Chen, Chiou-Feng Lin   +7 more
doaj   +1 more source

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents

Journal of Hematology & Oncology, 2023
Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all NHLs and characterized by overexpression of cyclin D1. The last decade has seen the development of many novel treatment approaches in MCL, most notably the class of ...
Neeraj Jain, Mukesh Mamgain, Sayan Mullick Chowdhury, Udita Jindal, Isha Sharma, Lalit Sehgal, Narendranath Epperla   +6 more
doaj   +1 more source

Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway

Frontiers in Immunology, 2021
Since the first clinical report in 2013, inhibitors of the intracellular kinase BTK (BTKi) have profoundly altered the treatment paradigm of B cell malignancies, replacing chemotherapy with targeted agents in patients with chronic lymphocytic leukemia ...
C. I. Edvard Smith, Jan A. Burger
doaj   +1 more source

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma

BMC Cancer, 2021
Background The more selective second-generation BTK inhibitors (BTKi) Acalabrutinib and Zanubrutinib and the first-generation BTKi Ibrutinib are highlighted by their clinical effectiveness in mantle cell lymphoma (MCL), however, similarities and ...
Zhuojun Liu, Jia Liu, Tianming Zhang, Lin Li, Shuo Zhang, Hao Jia, Yuanshi Xia, Mingxia Shi, Jing Zhang, Shuhua Yue, Xiaofang Chen, Jian Yu   +11 more
doaj   +1 more source

Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia

Journal of Hematology & Oncology, 2023
Background The treatment landscape for chronic lymphocytic leukemia (CLL) continues to undergo considerable evolution. Optimal selection of initial therapy from multiple effective options provides a major challenge for clinicians, who need to consider ...
Rory Bennett, Mary Ann Anderson, John F. Seymour   +2 more
doaj   +1 more source

Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study [PDF]

, 2023
Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments is limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy.
Zinzani P. L., Park J. E., Siddiqi R., Vilmar A., Fischer L., Gine E., Jerkeman M., Reitan J., Keeping S., Sancho J. -M., Wade S., Dreyling M., Thieblemont C., Hess G., Zilioli V. R., Chen J. M. H., Oberic L., Ubieto A. J., Lambert J., Stilgenbauer S., Eyre T. A., Salles G., Linton K., Wu J. J., Ohler A.   +24 more
core   +3 more sources

Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and in vitro Bleeding Time

Frontiers in Cardiovascular Medicine, 2021
Background: Bruton tyrosine kinase inhibitors (BTKi) are used in B-cell malignancies and in development against various autoimmune diseases. Since Btk is also involved in specific pathways of platelet activation, BTKi might be considered to target ...
Rundan Duan, Luise Goldmann, Richard Brandl, Michael Spannagl, Christian Weber, Christian Weber, Christian Weber, Wolfgang Siess, Wolfgang Siess, Philipp von Hundelshausen, Philipp von Hundelshausen   +10 more
doaj   +1 more source